Efficiently Creating Value with Innovative Science


NASDAQ: OXGN

$ 0.66 0.04 (6.29%)
Day High: 0.74
Day Low:  0.66
Volume:    112,815
4:00 PM ET
Apr 29, 2016

Delayed ~20 min., by eSignal.

Press Releases

 
Press Releases
Date Title and Summary View
Mar 30, 2016 SOUTH SAN FRANCISCO, Calif., March 30, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CA4P for the treatment of platinum-resistant ovari...
Mar 28, 2016 SOUTH SAN FRANCISCO, Calif., March 28, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today reported financial results for 2015. For the year ended December 31, 2015, OXiGENE reported a net loss of $13.7 million compared to a net loss...
Mar 25, 2016 SOUTH SAN FRANCISCO, Calif., March 25, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that the European Commission has granted orphan drug designation to CA4P for the treatment of gastro-entero-pancreatic neuroendocrine tum...
Mar 24, 2016 SOUTH SAN FRANCISCO, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that Simon C. Pedder, Ph.D. has been appointed to OXiGENE's board of directors, effective March 21, 2016. "I am extremely pleased ...
Feb 3, 2016 SOUTH SAN FRANCISCO, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced it will present a company overview on February 8, 2016 at 11:30 a.m. Eastern time at the 2016 BIO CEO & Investor Forum. ...
Jan 6, 2016 SOUTH SAN FRANCISCO, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CA4P for the treatment of neuroendocrine tumors. T...
Dec 17, 2015 SOUTH SAN FRANCISCO, Calif., Dec. 17, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that the European Commission has granted orphan drug designation to OXi4503 for the treatment of acute myeloid leukemia (AML). The designa...
Nov 10, 2015 SOUTH SAN FRANCISCO, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today reported financial results for the quarter ended September 30, 2015. For the third quarter of 2015, OXiGENE reported a net loss of $3.6 millio...
Nov 5, 2015 SOUTH SAN FRANCISCO, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced initial data from a Phase 1b/2 study of the company's lead investigational drug, CA4P, in combination with the anti-angiogenic agent Votrient...
Oct 21, 2015 First patient dosed in OXiGENE-sponsored expansion of investigator trial Phase 1b/2 dose-escalation study of OXi4503 as a single agent and in combination with cytarabine SOUTH SAN FRANCISCO, Calif., Oct. 21, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents ...
Page:
1
... NextLast
= add release to Briefcase